Lantern Pharma (NASDAQ: LTRN), an AI company developing targeted cancer therapies using its proprietary RADR® AI and machine learning platform, announced that management will present at the ThinkEquity Conference on Oct. 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York City. The presentation will be available via live webcast, and Lantern Pharma management will be available for one-on-one investor meetings throughout the conference. To view the full press release, visit https://ibn.fm/hmTGq.
The ThinkEquity Conference is a notable gathering for investors and companies in emerging growth sectors, and Lantern Pharma’s participation underscores its commitment to engaging with the investment community. The company’s RADR® platform integrates large-scale genomic and biological data with advanced machine learning to transform the cost, pace, and precision of oncology drug development. By identifying patients most likely to benefit from its therapies and guiding biomarker-driven clinical development, RADR® aims to streamline the drug development process and improve outcomes.
Lantern Pharma’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. These programs target various cancer indications, and the company’s AI-driven approach could potentially accelerate the delivery of new treatments to patients. For investors, the presentation may provide insights into upcoming milestones, clinical trial progress, and the potential of the company’s AI platform to address unmet needs in oncology.
The announcement is being distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
For Lantern Pharma, the ThinkEquity Conference represents an opportunity to showcase its AI-driven approach to a targeted audience of investors and analysts. The company’s ability to leverage artificial intelligence in drug development could position it as a leader in the evolving landscape of precision oncology. As the conference approaches, stakeholders will be watching for updates on Lantern Pharma’s clinical programs and any potential partnerships or collaborations that could further validate its RADR® platform.
Investors and other interested parties can access the live webcast of the presentation, and management will be available for one-on-one meetings, providing a chance for deeper engagement. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. With its participation in the ThinkEquity Conference, Lantern Pharma is poised to maintain visibility in the investment community and potentially attract new interest in its mission to transform oncology drug development.
